News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Emerging Growth Equities, Ltd. Initiates Coverage of Sarepta Therapeutics (Formerly known as AVI BioPharma, Inc.) (SRPT) (SRPT) With a BUY Rating and $38.00 Price Target


3/12/2013 9:49:26 AM

KING OF PRUSSIA, Pa., March 11, 2013 /PRNewswire/ -- Emerging Growth Equities, Ltd. initiates coverage of Sarepta Therapeutics, Inc. (NASDAQ: SRPT) with a BUY rating and a $38.00 price target. Sarepta Therapeutics, Inc. focuses on the discovery and development of RNA-based therapeutics for the treatment of rare and infectious diseases.

Emerging Growth Equities, Ltd., is a specialty brokerage and investment banking firm that provides high quality distribution, research and trade execution for institutional and retail clients. Emerging Growth Equities, Ltd. specializes in fulfilling the capital requirements of well-managed emerging growth companies.

Institutional investors may call their Emerging Growth Equities, Ltd. sales person for a full text of the report at 610-783-1800.

This publication is neither an offer to sell nor a solicitation to buy any securities mentioned herein. The information contained herein is based on data obtained from recognized sources that are believed to be reliable. Emerging Growth Equities, Ltd. has not independently verified the facts, assumptions and estimates contained in this report. Accordingly, no representation or warranty, expressed or implied, is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of the information and opinions contained in this report. The information contained in this report is not and does not purport to be a complete analysis of every material fact respecting any company, industry, or security.

Most of the companies Emerging Growth Equities, Ltd. follows are emerging and mid-sized growth companies whose securities typically involve a higher degree of risk and more volatility than the securities of more established companies. For these and other reasons, the investments discussed or recommended in this report may be unsuitable for investors depending on their specific investment objectives and financial position. Transactions in securities mentioned herein may be effected only in those states where such securities are qualified for sale.

Any statements nonfactual in nature herein constitute only current opinions or estimates, represent only the current judgment of the author(s), and are subject to change without notice. This report contains forward-looking statements, which involve risks and uncertainties. Actual results may differ significantly from the results described in the forward-looking statements. Emerging Growth Equities, Ltd. (or one of its affiliates) or their partners, officers, directors, analysts, employees or customers may have an interest in the securities mentioned herein and may make purchases or sales as principal or agent of these securities, or their derivatives, while this report is in circulation. A partner, employee, analyst, officer, or director of Emerging Growth Equities, Ltd. (or one of its affiliates) may serve as a director or consultant for any company mentioned herein. Emerging Growth Equities, Ltd. (or one of its affiliates) may from time to time perform investment banking services for, or solicit investment banking business or other business from, any company mentioned herein. Additional information on the securities discussed herein is available on request. © Copyright 2013 Emerging Growth Equities, Ltd.

Emerging Growth Equities, Ltd. is a member of the Financial Industry Regulatory Authority, CRD number 47040.

Contact:

Debjit Chattopadhyay, Ph.D., MBA


Director of Research


610-783-4782 or 888-293-1800

SOURCE Emerging Growth Equities, Ltd.


Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES